# Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Study · id `cardio:ct-nct02630316` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02630316](<https://clinicaltrials.gov/study/NCT02630316>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02630316

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 326 participants.

## Technical summary

Registry record NCT02630316. Randomized; quadruple masking; primary purpose treatment. Start 2017-02-03 (actual); primary completion 2019-12-26 (actual). Results posted on 2021-07-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 326 participants (enrolled count; ClinicalTrials.gov record NCT02630316, source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)
- Started: 2017-02-03 (actual) (ClinicalTrials.gov record NCT02630316, source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)
- Primary completion: 2019-12-26 (actual) (ClinicalTrials.gov record NCT02630316, source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)
- Completion: 2019-12-26 (actual) (ClinicalTrials.gov record NCT02630316, source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)
- Results first posted: 2021-07-13 (ClinicalTrials.gov record NCT02630316, source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02630316, source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02630316-2022-07-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Condition: Pulmonary Hypertension
- Condition: Interstitial Lung Disease
- Condition: Combined Pulmonary Fibrosis and Emphysema
- Intervention (Drug): Inhaled Treprostinil
- Intervention (Drug): Placebo
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease (`cardio:pubmed-33440084`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study (`cardio:pubmed-34214475`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes (`cardio:pubmed-36115497`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cf29aef1ec69f438ef71a27735f4efedbfa5fd53c90740cd86a7a0e5f789547c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
